New trends in treatment of hypertrophic cardiomyopathy

Archives of Cardiovascular Diseases

Volumn 102, Issue 5, 2009, Pages 441-447

  Hagège, Albert A ^a,b   Desnos, Michel ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSERM   (France)

Author keywords

Alcohol septal ablation; Hypertrophic cardiomyopathy; Implantable cardiac defibrillator

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DISOPYRAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPRANOLOL; VERAPAMIL;

ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE REGULATION; CATHETER ABLATION; DEFIBRILLATOR; EXERCISE; FOLLOW UP; HEART ARREST; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PACING; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MITRAL VALVE DISEASE; MORTALITY; MUSCLE RESECTION; OVERALL SURVIVAL; PRESYNCOPE; QUALITY OF LIFE; REVIEW; SUDDEN DEATH; SYNCOPE; TREATMENT INDICATION;

EID: 67650556331     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2009.03.008     Document Type: Review

References (45)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-1320
2. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large nonreferral-based patient population. Circulation 2000;102:858-864 (Pubitemid 30671501)
3. Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301-307 (Pubitemid 34084637)
4. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006;92:785-791 (Pubitemid 43799212)
5. Woo A, Monakier D, Harris L, et al. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart 2007;93:1044-1045 (Pubitemid 47310979)
6. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high-risk patients. J Am Coll Cardiol 2000;36:2212-2218
7. Saumarez RC, Pytkowski M, Sterlinski M, et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 2008;29:1653-1661 (Pubitemid 351957538)
8. Nazarian S, Lima JA. Cardiovascular magnetic resonance for risk stratification of arrhythmia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008;51:1375-1376
9. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-2524 (Pubitemid 33107372)
10. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303. (Pubitemid 36119984)
11. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-1941 (Pubitemid 44297366)
12. Nistri S, Olivotto I, Betocchi S, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006;98:960-965 (Pubitemid 44402269)
13. Dimitrow PP, Undas A, Bober M, et al. Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. Heart 2008;94:e21.
14. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114:2232-2239 (Pubitemid 44789498)
15. Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008;117:429-439
16. Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart 2008;94:1276-1281
17. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-1991
18. Nishimura RA, Holmes Jr DR. Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004;350:1320-1327
19. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:1251-1258 (Pubitemid 40523146)
20. Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99:254-261 (Pubitemid 29056368)
21. Pacing in Cardiomyopathy (PIC) Study GroupKappenberger LJ, Linde C, Jeanrenaud X, et al. Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Europace 1999;1:77-84.
22. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997;29:435-441 (Pubitemid 27059978)
23. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999;99:2927-2933
24. Binder J, Ommen SR, Sorajja P, et al. Clinical and echocardiographic variables fail to predict response to dual-chamber pacing for hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2008;21:796-800.
25. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
26. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-373 (Pubitemid 30084534)
27. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverterdefibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-412 (Pubitemid 47124061)
28. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214 (Pubitemid 26001850)
29. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-2421 (Pubitemid 28549785)
30. Seggewiss H. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 2000;21:704-707 (Pubitemid 30201360)
31. Angelini P. The "1st septal unit" in hypertrophic obstructive cardiomyopathy: a newly recognized anatomofunctional entity, identified during recent alcohol septal ablation experience. Tex Heart Inst J 2007;34:336-346
32. Sigwart U. Catheter treatment for hypertrophic obstructive cardiomyopathy: for seniors only? Circulation 2008;118:107-108
33. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008;118:131-139
34. Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice. Heart 2008;94:1269-1275
35. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-476 (Pubitemid 41040288)
36. Jiang L, Levine RA, King ME, et al. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiography observations. Am Heart J 1987;113:633-644 (Pubitemid 17036711)
37. Levine RA, Vlahakes GJ, Lefebvre X, et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circulation 1995;91:1189-1195
38. He S, Hopmeyer J, Lefebvre XP, et al. Importance of leaflet elongation in causing systolic anterior motion of the mitral valve. J Heart Valve Dis 1997;6:149-159 (Pubitemid 27166176)
39. Delling FN, Sanborn DY, Levine RA, et al. Frequency and mechanism of persistent systolic anterior motion and mitral regurgitation after septal ablation in obstructive hypertrophic cardiomyopathy. Am J Cardiol 2007;100:1691-1695 (Pubitemid 350122334)
40. Yamazaki T, Suzuki J, Shimamoto R, et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. Int Heart J 2007;48:715-724
41. Senthil V, Chen SN, Tsybouleva N, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rab- bit model of human hypertrophic cardiomyopathy. Circ Res 2005;97:285-292 (Pubitemid 41105455)
42. Prasad K, Williams L, Campbell R, et al. Episodic syncope in hypertrophic cardiomyopathy: evidence for inappropriate vasodilation. Heart 2008;94:1312-1317
43. Gaita F, Di Donna P, Olivotto I, et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007;99:1575-1581 (Pubitemid 46773025)
44. Durand E, Mousseaux E, Coste P, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J 2008;29:348-355 (Pubitemid 351197768)
45. Biagini E, Spirito P, Leone O, et al. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol 2008;101:387-392